These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34027879)

  • 1. Conservative Management of Thyroid Eye Disease.
    Khan SH; Malik U; Ahmed F; Siddiqui ZK; Munir S; Rashid N
    J Coll Physicians Surg Pak; 2021 May; 31(5):599-601. PubMed ID: 34027879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid eye disease: a review.
    Weiler DL
    Clin Exp Optom; 2017 Jan; 100(1):20-25. PubMed ID: 27701774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined thyroid eye clinic: the importance of a multidisciplinary health care in patients with Graves' orbitopathy.
    Wiersinga WM
    Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():250-3. PubMed ID: 20467372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thyroid ophthalmopathy at the time of European Group On Graves Orbitopathy (EUGOGO)].
    Sadoul JL
    Presse Med; 2011 Dec; 40(12 Pt 1):1163-73. PubMed ID: 22119334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Graves' ophthalmopathy.
    Wiersinga WM
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):396-404. PubMed ID: 17452966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Graves ophthalmopathy - 2022 update.
    Jiskra J
    Cas Lek Cesk; 2022; 161(5):198-206. PubMed ID: 36443100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
    Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
    Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Chinese survey of clinical practice on the management of thyroid eye disease.
    Chen J; Li C; Teng W; Shan Z; Jin J; Wei Y; Sun J; Li Y; Zhou H
    Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Endocrine orbitopathy: the present view of a clinical endocrinologist].
    Jiskra J
    Vnitr Lek; 2017; 63(10):690-696. PubMed ID: 29127744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life of patients with thyroid eye disease: 3-year follow-up in a multidisciplinary clinic in Israel.
    Zloto O; Sagiv O; Priel A; Cukierman-Yaffe T; Tirosh A; Agmon-Levin N; Madgar S; Serlin T; Ben Simon G
    Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):2009-2015. PubMed ID: 33528651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral conjunctivitis interfering with the clinical activity score and management of thyroid ophthalmopathy.
    Boboridis KG; Konstas AG; Krassas GE; Georgiadis NS
    Orbit; 2006 Mar; 25(1):27-9. PubMed ID: 16527772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Graves' ophthalmopathy from the internist's perspective].
    Laubner K; Weber WA; Seufert J
    Ophthalmologe; 2011 May; 108(5):410-6. PubMed ID: 21590351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management plan and delivery of care in Graves' ophthalmopathy patients.
    Yang M; Perros P
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):303-11. PubMed ID: 22632367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
    Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A symposium on thyroid-associated ophthalmopathy, also known as Graves' orbitopathy at the Jules Stein Eye Institute at the University of California, Los Angeles.
    Douglas RS; Goldberg RA; Smith TJ
    Thyroid; 2008 Sep; 18(9):931. PubMed ID: 18788916
    [No Abstract]   [Full Text] [Related]  

  • 16. A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.
    Farag S; Feeney C; Lee V; Nagendran S; Jain R; Aziz A; Akishar R; Bravis V; Meeran K
    Front Endocrinol (Lausanne); 2021; 12():669871. PubMed ID: 34025584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of Graves' orbitopathy: evidence-based recommendations].
    Ponto KA; Pitz S; Mann WJ; Weber MM; Pfeiffer N; Kahaly GJ
    Dtsch Med Wochenschr; 2009 Dec; 134(49):2521-4. PubMed ID: 19941237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is differential diagnosis of thyroid-associated ophthalmopathy easy].
    Wang Y
    Zhonghua Yan Ke Za Zhi; 2021 Nov; 57(11):809-813. PubMed ID: 34743464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thyroid associated orbitopathy: from diagnosis to treatment].
    Hamédani M; Obéric A
    Rev Med Suisse; 2013 Jan; 9(368):66-71. PubMed ID: 23367708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.